Trial Profile
Phase II Trial of PF-00299804 in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of Platinum-containing Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Aug 2015
Price :
$35
*
At a glance
- Drugs Dacomitinib (Primary)
- Indications Head and neck cancer; Laryngeal cancer; Orofacial cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 29 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Apr 2014 Results presented at the 105th Annual Meeting of the American Association for Cancer Research.
- 03 Jul 2013 Planned end date changed from 1 Apr 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.